Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 6540-33-6 | MDL No. : | MFCD06411067 |
Formula : | C6H10O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | FQRMJJJRCOMBKG-UHFFFAOYSA-N |
M.W : | 114.14 | Pubchem ID : | 1516411 |
Synonyms : |
|
Num. heavy atoms : | 8 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.83 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 30.61 |
TPSA : | 37.3 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.02 cm/s |
Log Po/w (iLOGP) : | 1.39 |
Log Po/w (XLOGP3) : | 1.38 |
Log Po/w (WLOGP) : | 1.26 |
Log Po/w (MLOGP) : | 0.88 |
Log Po/w (SILICOS-IT) : | 1.06 |
Consensus Log Po/w : | 1.2 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -1.29 |
Solubility : | 5.92 mg/ml ; 0.0519 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.77 |
Solubility : | 1.95 mg/ml ; 0.0171 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.48 |
Solubility : | 37.8 mg/ml ; 0.331 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.4 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
88.9% | at 120℃; for 16 h; | Step 2: A solution of 53_2 (15.00 g, 157.66 mmol, 1.00 eq) in HC1 (6 M, 150 mL, 5.71 eq) was stirred at 120°C for 16 hours. The mixture was diluted with water (500 mL) and extracted with EtOAc (200mL*2). The combined organic layers were washed with water (400 mL). The organic layer was dried and concentrated to give 53_3 (16.00 g, 140.18 mmol, 88.9percent yield) as a colorless liquid. NMR (CDC13, 400 MHz) δ 2.69-2.68 (m, 1 H), 2.47-2.45 (m, 2 H), 2.17-2.15 (m, 2H), 1.89-1.87 (m, 2H), 1.75-1.70 (m, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
64% | Stage #1: With magnesium In tetrahydrofuran at 20℃; for 18 h; |
Blank magnesium chips (370 mg, 15.2 mmol) were covered with abs. THF (ca. 0.5 mL). Two drops283 (bromomethyl)cyclobutane (from 2.09 g, 14.0 mmol) were added. As the reaction started, the rest of284 the bromide was solved in abs. THF (4 mL) and the solution was added dropwise with stirring. After285 addition, the mixture was allowed to stand for 18 h at room temperature. The mixture was diluted286 abs. THF (10 mL), warmed near to reflux und slowly poured on crushed dry ice (100 mL). After287 warming up to about 0 °C and addition of EtOAc (10 mL), the mixture was washed with 2 M HCl (10288 mL) and saturated with NaCl. The organic layer was separated and the aqueous layer was extracted289 with EtOAc (10 mL), the combined organic layers were dried over Na2SO4 and concentrated under290 reduced pressure resulting in 1.02 g cyclobutylacetic acid (7a) (64 percent). |
[ 7439-33-0 ]
trans-Cyclobutane-1,3-dicarboxylic acid
Similarity: 0.90
[ 1124-13-6 ]
trans-Cyclobutane-1,2-dicarboxylic acid
Similarity: 0.90
[ 57252-83-2 ]
3-Methylcyclobutanecarboxylic acid
Similarity: 0.90